WATERTOWN, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, will host a conference call on Tuesday, August 9, 2016, at 8:30 a.m., Eastern Time. During the call, management will review the company’s second quarter 2016 financial results and provide a corporate update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company's website at www.selectabio.com or by dialing (844) 309-6574 (U.S./Canada) or (484) 747-6923 (International), with the passcode 56175357.
About Selecta
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system.
Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases.
Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases.
Selecta is based in Watertown, Massachusetts, USA.